TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06970795: An Open-lable, Multicenter Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of SYS6040 for Injection as a Single Agent in Participants With Advanced Solid Tumo

Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 180 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06970795 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06970795 Rescue Dossier →